No Data
Leap LLC Secures Spot on the Inc. 5000 Fastest-Growing Companies List for the Fourth Consecutive Year
Baird Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $9
Optimistic Buy Rating on Leap Therapeutics Amid Promising Phase 2 Cancer Trial Outcomes
H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5
Leap LLC Welcomes Jason Tillery as New Board Member: A Strategic Move to Enhance AI Capabilities
Express News | Leap Therapeutics Q2 2024 GAAP EPS $(0.52) Misses $(0.43) Estimate, Cash And Cash Equivalents Totaled $78.5M At June 30, 2024, Expected To Fund Leap's Operating And Capital Expenditures Into Q2 Of 2026
No Data
Jaguar8 : Love it
Trytosaveabit OP Jaguar8 : Right! What’s Gilead up to? Hehehe
Jaguar8 Trytosaveabit OP : I sense they will eventually buy this out
买跌不追涨 : You can rest early today, don't be so tired. Have a nice weekend
BelleWeather : Interesting choice. I’m going to do DD with a focus on the science. I hope it pans out and they get bought out.
View more comments...